- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05765994
Small Intestinal Bacterial Overgrowth in Critically Ill Patients
The Effects of Small Intestinal Bacterial Overgrowth Syndrome in ICU Patients. An Observational Study
Small intestinal bacterial overgrowth (SIBO) syndrome, though associated with potentially serious complications, has not been adequately studied to date in critically ill patients hospitalized in intensive care units (ICU).
A modified method for SIBO diagnosis is employed concerning a standard breath test. Specifically, as all participants are intubated and in need of mechanical ventilation, SIBO diagnosis is based on a non-invasive modified technique for sampling exhaled air from the ventilator tubes and performing a standard hydrogen breath test.
The primary objective of this study is assessment of the prevalence of SIBO on ICU patients. Secondary outcomes include investigation of the effects of SIBO on ventilator associated pneumonia, as well as ICU length of stay and all-cause in-hospital mortality rate in critically ill patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
Small intestine bacterial overgrowth (SIBO) remains to this day a syndrome that is not fully understood. Initially, it was considered quite rare, but today there are reports suggesting a SIBO prevalence between 6 to 15% of healthy, asymptomatic people and reaching 80% in patients with irritable bowel syndrome. It is often involved in various disorders, such as diarrhea and malabsorption. It is defined as an increase in the number and/or disturbance in the type of bacteria in the upper part of the intestinal tract.
SIBO occurs when the homeostatic mechanisms of the small intestine are disturbed. The two main conditions that favor microbial overgrowth in the small intestine are decreased acid secretion from the stomach and small bowel dyskinesia.
The literature is scarce concerning the effects of SIBO on critically ill patients. To our knowledge this is the first study investigating the effects of SIBO on mechanically ventilated patients. It is a non-invasive observational study employing a modified technique to obtain exhaled air from the ventilator tubes to perform a standard hydrogen breath test for SIBO diagnosis. Lactulose is used as a substrate. Specifically, each patient is administered 20 g of lactulose diluted in 400 ml of water through the nasogastric tube. Measurements are performed at 0-15-30-45-60-90-120-180 min from lactulose administration. During measurements, a valve attached to a collecting bag at the end of the expiratory limb of the breathing circuit, is kept open and the collecting bag is filled by several patient exhalations. After valve closure and bag isolation, the air is drawn by a 50 ml polyethylene syringe which is connected to the valve system to prevent losses and/or contamination. Then the air is blown into the breath hydrogen monitor and the expired hydrogen measurement is recorded.
The hydrogen breath test is repeated at predetermined, protocol-based time intervals for all participants included in the study; 1st/day of admission, 3rd, 5th and 7th day of ICU stay. The 1st day measurement serves as a measure of eligibility, and patients exhibiting abnormal values of hydrogen breath testing at Day 1 are excluded from the study.
An increase by more than 20 ppm of eH2 from baseline within 90 min was considered an abnormal measurement suggesting SIBO. Moreover, an increase by more than 12 ppm of eH2 from baseline within the first 30 minutes followed by a second rise within the next 15 minutes (double peak) was also considered an abnormal measurement suggesting SIBO.
The primary objective of this study is assessment of the prevalence of SIBO on critically ill mechanically ventilated ICU patients. Secondary outcomes include investigation of the effects of SIBO on ventilator associated pneumonia, as well as ICU length of stay and all-cause in-hospital mortality rate in critically ill patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Epirus
-
Ioannina, Epirus, Greece, 45500
- Univesity Hospital of Ioannina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- critically ill patients, in need of mechanical ventilation with an expected ICU length of stay and expected mechanical ventilation duration of more than 48 hours
Exclusion Criteria:
- abnormal hydrogen breath test on the day of ICU admission (Day 1)
- recent (up to four weeks before ICU admission) antimicrobial therapy or patients already receiving antimicrobial therapy on admission
- recent (up to four weeks before ICU admission) use of gastroprotective medication, probiotics and prokinetics
- patients with known gastrointestinal disease prior to admission
- recent abdominal surgery resulting in planned or unplanned ICU admission
- extubation or death before protocol completion (7 days) constitute exclusion criteria after enrollment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ICU patients
Adult ICU patients on mechanical ventilation
|
A modified technique to obtain expired hydrogen from the ventilator tubes is performed.
A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SIBO prevalence
Time Frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
The proportion of ICU patients diagnosed with SIBO
|
From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAP (ventilator associated pneumonia)
Time Frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
The proportion of ICU patients diagnosed with VAP
|
From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
ICU LOS
Time Frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
ICU lenght of stay, days
|
From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
All-cause in-hospital mortality
Time Frame: From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
Death due to any cause during ICU and hospital stay.
|
From date of ICU admission to date of ICU discharge or date of death from any cause, whichever came first, assessed up to one month)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 207
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Yale UniversityNational Institute on Aging (NIA)RecruitingCritical Illness | Illness, CriticalUnited States
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Boston Children's HospitalCompleted
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
-
University Hospital Birmingham NHS Foundation TrustCompletedRehabilitation After Critical Illness
-
Hospital de Clinicas de Porto AlegreUnknownCritical Illness PolyneuropathiesBrazil
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Insel Gruppe AG, University Hospital BernMonash UniversityNot yet recruitingMuscle Weakness | Critical Illness Myopathy | Physical Inactivity | Critical Illness Polyneuropathy | Critical Illness PolyneuromyopathySwitzerland
-
Peking Union Medical College HospitalBaxter Healthcare CorporationUnknownNutrition Therapy for Critical Illness
Clinical Trials on Modified hydrogen breath test
-
Yonsei UniversityUnknownIrritable Bowel SyndromeKorea, Republic of
-
VenterPharmaCompleted
-
QOL Medical, LLCCompletedCongenital Sucrase-Isomaltase DeficiencyUnited States
-
Asian Institute of Gastroenterology, IndiaRecruitingIrritable Bowel Syndrome | Small Bowel Disease | Motility DisorderIndia
-
Brain-Gut Research GroupNational University, Singapore; New Jersey Medical SchoolCompletedIrritable Bowel Syndrome | Functional Gastrointestinal DisordersSwitzerland
-
Mebo Research, Inc.Aurametrix; Menssana Research, Inc.CompletedNutritional and Metabolic DiseasesUnited States, United Kingdom
-
Shandong UniversityJinan Central Hospital; Weihai Municipal Hospital; Weifang People's Hospital; Qilu... and other collaboratorsNot yet recruiting
-
The Cleveland ClinicAbbVieRecruitingCrohn Disease | Ulcerative Colitis | IBDUnited States
-
Imperial College LondonUniversity College London Hospitals; Northern Care Alliance NHS Foundation... and other collaboratorsRecruitingBarrett Esophagus | Oesophageal Cancer | Barretts Esophagus With DysplasiaUnited Kingdom
-
Meir Medical CenterUnknownMetabolic State, Breath Analysis, NA-Nose